Healthcare AI: Where to Invest Across 8 Clinical Domains

The promise of artificial intelligence in healthcare is vast, but its practical application and commercial viability are deeply nuanced, particularly when viewed through the lens of specific therapeutic areas. As investors and clinicians navigate this rapidly evolving landscape, a critical question emerges: where is AI truly delivering validated impact, and where does the hype still outweigh the evidence? This article dissects the healthcare AI market by therapeutic area, offering a structured market map that distinguishes between established efficacy and emerging potential across eight clinical domains.

Mapping the Healthcare AI Landscape by Therapeutic Area

The healthcare AI market is not monolithic; its maturity and impact vary significantly across different clinical domains. While radiology has historically dominated the sheer volume of AI applications, accounting for approximately 76% of all FDA-cleared AI algorithms [CW3-DP-01], a deeper dive reveals a more complex picture. Notably, within this broad landscape, cardiac AI often presents the strongest per-company evidence, a testament to rigorous validation pathways and clear clinical needs. This distinction is crucial for investors seeking de-risked opportunities and for clinicians evaluating tools for integration into practice. Consider the trajectory of companies like Viz.ai and HeartFlow in the cardiovascular space. Viz.ai, leveraging AI for stroke detection and care coordination, has demonstrated the ability to significantly reduce time to treatment, a critical factor in neurological outcomes. HeartFlow, with its AI-powered FFRct analysis, provides non-invasive functional assessment of coronary artery disease, moving beyond anatomical stenosis to physiological significance. Both companies operate in domains where timely and accurate diagnosis directly impacts patient mortality and morbidity, driving robust clinical validation. Contrast this with the broader “general health AI” or “consumer wellness AI” categories, where validation can be more elusive. Companies such as Omada Health, which completed an IPO in June 2025 and reported $78 million in revenue for Q1 2026, Virta Health, which surpassed $160 million in annualized revenue as of September 2025, and Hinge Health, while addressing significant health challenges like chronic disease management and musculoskeletal conditions, often rely on behavioral economics and digital coaching. Their evidence typically stems from improvements in health metrics and cost reduction, rather than direct diagnostic or interventional efficacy that requires stringent regulatory pathways like FDA 510(k) or De Novo classification. The pathology and oncology domains are also seeing significant AI integration, with companies like Tempus AI, PathAI, Paige, and Lunit leading the charge. Tempus AI focuses on precision medicine by analyzing clinical and molecular data, aiding in therapeutic selection for cancer patients, and has recently received multiple FDA clearances, including for its RNA-based Tempus xR IVD device, an updated Tempus Pixel cardiac imaging platform, and its ECG-Low EF software. PathAI and Paige are developing AI tools for digital pathology, assisting pathologists in cancer diagnosis and prognosis. Paige recently raised $81.25 million in funding and received FDA 510(k) clearance for its FullFocus™ digital pathology image viewer, as well as Breakthrough Device designation for its PanCancer Detect. Lunit, similarly, applies AI to medical imaging for cancer detection, and received FDA clearance for version 1.2 of its 3D mammography AI algorithm in April 2026. These applications are moving towards a higher bar of evidence, often seeking FDA clearances for diagnostic support. Even in dentistry, Overjet applies AI to analyze dental X-rays, assisting practitioners in identifying and quantifying pathologies, and has recently secured FDA clearances for AI-powered image enhancement and its CBCT Assist product for 3D imaging. Digital Diagnostics, meanwhile, holds a unique position with the first FDA De Novo authorization for an autonomous AI diagnostic system for diabetic retinopathy. This distinction highlights a critical aspect of validation: the regulatory path chosen reflects the intended use and the level of clinical evidence required. As Dr. Eric Topol has frequently articulated, the true value of AI in medicine lies not just in its computational power, but in its ability to augment human expertise and deliver demonstrable improvements in patient care. Similarly, Dr. Adam Rodman, a proponent of evidence-based medicine, would likely emphasize the necessity of rigorous clinical trials and real-world evidence (RWE) to substantiate AI claims, moving beyond mere technical capability to proven clinical utility. The distinction between AI that assists and AI that autonomously diagnoses is paramount, especially when considering regulatory oversight and clinical adoption.

Regulatory Frameworks and Industry Standards

The regulatory landscape is the bedrock upon which validated healthcare AI solutions are built. The FDA’s Center for Devices and Radiological Health (CDRH) plays a pivotal role in ensuring the safety and effectiveness of AI/ML-driven medical devices. Companies pursuing high-stakes clinical applications, particularly those involving diagnosis or treatment decisions, must navigate pathways such as FDA 510(k) clearance, De Novo classification, or even premarket approval (PMA) for novel, high-risk devices. FDA guidance on AI/ML medical devices A 510(k) clearance, the most common pathway, demonstrates substantial equivalence to a legally marketed predicate device. This is often the route for AI tools that automate or enhance existing diagnostic or analytical processes. De Novo classification is reserved for novel, low-to-moderate-risk devices where no predicate exists, signifying a truly innovative application. PMA, the most rigorous pathway, is for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. Beyond the FDA, professional organizations like the American Heart Association (AHA), American Diabetes Association (ADA), and American College of Radiology (ACR) are instrumental in developing guidelines and advocating for evidence-based integration of AI. Their consensus statements and recommendations often serve as crucial benchmarks for clinicians considering AI adoption and for investors assessing market readiness. For instance, the ACR has been particularly active in defining appropriate use criteria for AI in radiology, influencing how Viz.ai or Lunit’s imaging AI tools are evaluated and deployed. Similarly, the ADA’s stance on digital health interventions can impact the market perception and reimbursement potential for companies like Virta Health. The rigor of clinical evidence required by these regulatory bodies and professional associations is a significant differentiator. While radiology AI has a high volume of clearances, the depth of evidence for cardiac AI, as measured by per-company clinical trials and peer-reviewed publications, often stands out. This is not to diminish the innovation in other fields, but to highlight the varying evidentiary hurdles that different therapeutic areas face, and how these hurdles shape the competitive landscape.

The Imperative for Evidence in Healthcare AI

The future of healthcare AI hinges on its ability to consistently deliver validated, impactful solutions. For investors, this means prioritizing companies that demonstrate clear regulatory pathways, robust clinical evidence, and a pathway to reimbursement, rather than just technological prowess. For clinicians, it means demanding transparency, peer-reviewed outcomes, and adherence to established practice guidelines before integrating AI into patient care. The market map presented here underscores that while AI’s reach is expanding across eight clinical domains, the true value accrues where innovation is rigorously tested and clinically proven. The sheer volume of AI solutions in radiology (76% of FDA-cleared algorithms) [CW3-DP-01] might suggest maturity, but the strength of per-company evidence in cardiac AI indicates a different kind of validation. This distinction is critical for understanding where capital is best deployed and where clinical adoption is most likely to accelerate. As the industry matures, the focus will increasingly shift from “can AI do this?” to “has AI proven its value in a real-world clinical setting, and is it regulated appropriately?” The companies that successfully navigate this shift, grounded in robust evidence and regulatory compliance, will be the ones to truly redefine healthcare. Peer-reviewed analysis of healthcare AI regulatory approvals